Market revenue in 2023 | USD 226.0 million |
Market revenue in 2030 | USD 312.2 million |
Growth rate | 4.7% (CAGR from 2023 to 2030) |
Largest segment | Infectious diseases |
Fastest growing segment | Oncology |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Oncology, Prenatal Testing, Endocrinology, Other Applications, Hematology, Infectious Diseases |
Key market players worldwide | Roche, Abbott Laboratories, Qiagen NV, Bayer AG, Nova Biomedical, Danaher Corp, Nipro Corp, Bio-Rad Laboratories Inc, Agilent Technologies Inc, BioMerieux SA, OraSure Technologies Inc, Abaxis |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to point-of-care molecular diagnostics market will help companies and investors design strategic landscapes.
Infectious diseases was the largest segment with a revenue share of 93.45% in 2023. Horizon Databook has segmented the China point-of-care molecular diagnostics market based on oncology, prenatal testing, endocrinology, other applications, hematology, infectious diseases covering the revenue growth of each sub-segment from 2018 to 2030.
Japan’s National Health Insurance System reimburses almost all locally available POC molecular diagnostics products. It is not legal in Japan to purchase devices that the government has not approved for reimbursement. Some devices are reimbursed based on product category, while others are reimbursed through procedure fees.
The reimbursement rate for devices is revised every 2 years. In Japan, reimbursement usually takes 9 months post product approval. However, if manufacturers try to categorize a product into a higher reimbursement class or increase reimbursement, the procedure can take more than 1 year.
Horizon Databook provides a detailed overview of country-level data and insights on the China point-of-care molecular diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into China point-of-care molecular diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account